Quizartinib maintenance for FLT3-ITD AML in remission
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests two different doses of an oral targeted pill called quizartinib (a FLT3 inhibitor) to keep AML with a FLT3-ITD mutation in remission after initial chemo. If you are in first complete remission and haven't had a transplant, this might be an option to lower the chance of relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have a new diagnosis of AML with a specific gene change called FLT3-ITD.
- You need to be in your first complete remission (CR1) after 1 or 2 cycles of induction chemo, with or without a FLT3 inhibitor.
- You must not have received a stem cell transplant for your AML, or more than 4 cycles of consolidation chemo.
- You should have normal blood cell counts (ANC >1000 and platelets >100) and be able to start maintenance within 60 days of your last consolidation.
- Your heart function needs to be good (no serious arrhythmias, heart block, or recent heart attack; QTcF ≤450 ms).
- You cannot be taking strong or moderate CYP3A inducers (certain drugs) 2 weeks before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of anti-leukemia drugs (including quizartinib) together with chemotherapy for people with acute myeloid leukemia (AML), a rare mixed-type leukemia, or high-risk myelodysplastic syndrome (MDS). It may help by trying to better control cancer in people whose disease is newly diagnosed or has returned/not responded to prior treatment.
This trial tests two targeted drugs, ziftomenib and quizartinib, together for people with a certain type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal is to find the best dose and see if the combination helps.
This early-phase trial studies a 3-drug combination to treat certain types of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) in adults. It may help by targeting cancer cells using different medicines, especially for people who may not be able to get intensive chemotherapy.
This Phase 1 trial tests whether continuing decitabine alone or with other targeted drugs can help prevent AML from coming back after you reach remission. It’s designed to study safety and how well these maintenance options work for people who are not immediately able to get a stem cell transplant.
This trial tests a maintenance treatment called 'ITIVA' for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy and consolidation therapy. The goal is to see if this treatment helps keep the leukemia from coming back.
This trial tests if the drug ziftomenib can help prevent AML from coming back after a stem cell transplant. It is for people who have certain gene changes (KMT2A rearrangement or NPM1 mutation) and are in remission or near-remission before transplant.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.